ClinicaliQ Trial Snapshot
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors — Recruiting • Phase II • Oncology • NCT06535607.
- What is being tested: Volrustomig, a novel anti-cancer agent, is being evaluated both as a standalone treatment and combined with existing anti-cancer drugs in patients with advanced or metastatic solid tumors.
- Patient eligibility overview: The trial enrolls patients diagnosed with advanced or metastatic solid malignancies who meet specific disease stage criteria; detailed inclusion/exclusion criteria determine suitability for monotherapy versus combination treatment arms.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Eligibility Snapshot
- : * Age ≥18 at the time of signing the ICF. * Provision of tumor sample to assess the PD-L1 expression (if applicable). * ECOG performance status of 0 or 1. * Measurable disease according to RECIST 1.1 (variations of RECIST 1.1 if applicable). * Life expectancy ≥ 12 weeks. * Adequate organ and bone marrow function. * Body weight > 35 kg * Capable of giving signed informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.